Combining all the findings, it is possible to say that Morusflavone has the potential to form a stable interaction with the enzyme CYP17A1 that is similar to abiraterone, an FDA-approved inhibitor for prostate cancer. Here, CYP17A1 is linked to prostate carcinoma.